<DOC>
	<DOCNO>NCT02376400</DOCNO>
	<brief_summary>The purpose study test safety immunogenicity MVA-BN-Filo Ad26.ZEBOV administer heterologous prime-boost vaccine regimens healthy adult participant .</brief_summary>
	<brief_title>A Study Assess Safety Immunogenicity Heterologous Prime-Boost Ebola Vaccine Regimens Healthy Participants</brief_title>
	<detailed_description>This randomized placebo-controlled , double-blind study evaluate safety , tolerability immunogenicity MVA-BN-Filo Ad26.ZEBOV administer different sequence schedule healthy adult participant . The study consist screen period 28 day , vaccination period participant vaccinate Baseline [ Day 1 ] follow boost Day 29 57 post-boost follow-up , participant 21-day post-boost visit ( Day 50 Day 78 ) . The participant receive active vaccine enter long-term follow-up . The total duration study 1 year participant receive vaccine 3 month participant receive placebo . Immunogenicity safety monitor study .</detailed_description>
	<criteria>Must healthy basis physical examination , medical history , investigator 's clinical judgment Women childbearing potential must negative serum betahuman chorionic gonadotropin pregnancy test screening , negative urine pregnancy test immediately prior study vaccine administration , practice adequate birth control measure 28 day prime vaccination least 3 month boost vaccination specify study protocol . If heterosexually active screening , must agree practice adequate birth control measure become heterosexually active participation study ( screen onwards least 3 month boost vaccination ) . Must available willing participate duration study visit followup , provide verifiable identification , mean contact Has vaccinate candidate Ebola vaccine Has diagnose Ebola disease expose Ebola include travel West Africa last 12 month . West Africa include limited country Guinea , Liberia , Mali , Sierra Leone . Participants anticipate travel epidemic Ebola area start longterm followup period also exclude . During longterm followup period , travel epidemic Ebola area allow period sample take place participant return least 1 month epidemic Ebola area ensure sample carry Ebolavirus Has receive Ad26 MVAbased candidate vaccine past Known allergy history anaphylaxis serious adverse reaction vaccine vaccine product ( include constituent study vaccine ) , include know allergy egg aminoglycosides A woman pregnant breastfeeding , plan become pregnant enrolled study within 3 month boost vaccination History diabetes mellitus type 1 type 2 , include case control diet alone ; thyroidectomy , thyroid disease require medication last 12 month ; uncontrolled hypertension define study protocol ; , major psychiatric illness and/or substance abuse problem past 12 month opinion investigator would preclude participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Ebola virus</keyword>
	<keyword>Ebola Viral Disease ( EVD )</keyword>
	<keyword>Filoviruses</keyword>
	<keyword>Monovalent vaccine</keyword>
	<keyword>Human adenovirus serotype 26 ( Ad26 ) express Ebola virus Mayinga variant glycoprotein ( Ad26.ZEBOV )</keyword>
	<keyword>Modified Vaccinia Virus Ankara - Bavarian Nordic Filo-vector ( MVA-BN Filo )</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>